Center for Global Safe Water, Sanitation and Hygiene, Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Ifremer, Laboratoire de Microbiologie, BP 21105, 44311 Nantes cedex 03 France.
Epidemics. 2020 Sep;32:100401. doi: 10.1016/j.epidem.2020.100401. Epub 2020 Jul 17.
Noroviruses are a major public health concern: their high infectivity and environmental persistence have been documented in several studies. Genetic sequencing shows that noroviruses are highly variable, and exhibit rapid evolution. A few human challenge studies have been performed with norovirus, leading to estimates of their infectivity. However, such incidental estimates do not provide insight into the biological variation of the virus and the interaction with its human host. To study the variation in infectivity and pathogenicity of norovirus, multiple challenge studies must be analysed jointly, to compare their differences and describe how virus infectivity and host susceptibility vary. Since challenge studies can only provide a small sample of the diversity in the natural norovirus population, outbreaks should be exploited as an additional source of information. The present study shows how challenge studies and 'natural experiments' can be combined in a multilevel dose response framework. Infectivity and pathogenicity are analysed by secretor status as a host factor, and genogroup as a pathogen factor. Infectivity, characterized as the estimated mean infection risk when exposed to 1 genomic copy (qPCR unit)is 0.28 for GI norovirus, and 0.076 for GII virus, both in Se subjects. The corresponding risks of acute enteric illness are somewhat lower, about 0.2 (GI) and 0.035 (GII), in outbreaks. Se subjects are protected, with substantially lower risks of infection (0.00007 and 0.015 at a dose of 1 GC of GI and GII virus, respectively). The present study shows there is considerable variability in risk of infection and especially risk of acute symptoms following infection with norovirus. These challenge and outbreak data consistently indicate high infectivity among secretor positives and protection in secretor negatives.
多项研究记录表明,其具有高传染性和环境稳定性。基因测序表明,诺如病毒具有高度变异性,并表现出快速进化。已经进行了少数诺如病毒人体挑战研究,从而对其传染性进行了估计。然而,这些偶然的估计并不能深入了解病毒的生物学变异及其与人类宿主的相互作用。为了研究诺如病毒的传染性和致病性变异,必须联合分析多项挑战研究,以比较它们的差异,并描述病毒传染性和宿主易感性的变化。由于挑战研究只能提供天然诺如病毒群体多样性的一小部分样本,因此应该利用暴发作为额外的信息来源。本研究展示了如何在多层次剂量反应框架中结合挑战研究和“自然实验”。通过将分泌型状态作为宿主因素,以及基因型作为病原体因素来分析传染性和致病性。当暴露于 1 个基因组拷贝(qPCR 单位)时,GI 型诺如病毒的估计平均感染风险为 0.28,GII 型病毒为 0.076,均在 Se 个体中。急性肠道疾病的相应风险略低,暴发时约为 0.2(GI)和 0.035(GII)。Se 个体受到保护,感染风险大大降低(GI 和 GII 病毒的 1 GC 剂量分别为 0.00007 和 0.015)。本研究表明,感染诺如病毒的风险以及感染后急性症状的风险存在很大差异。这些挑战和暴发数据一致表明,分泌型阳性个体的传染性很高,而分泌型阴性个体受到保护。